Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 26:114838.
doi: 10.1016/j.jpeds.2025.114838. Online ahead of print.

Infant Renal Replacement Therapy Using Carpediem™: A Multicenter Observational Cohort Study from the ICONIIC Learning Network

Cara L Slagle  1 , Kim T Vuong  2 , Kelli A Krallman  3 , Lauren Casey  2 , Katja M Gist  4 , Jennifer G Jetton  5 , Catherine Joseph  2 , Kera Luckritz  6 , Susan D Martin  7 , Jolyn Morgan  8 , Kyle A Merrill  9 , Katie Plomaritas  6 , David Ramirez  10 , Cheryl L Tran  10 , H Stella Shin  11 , Amanda N Snyder  8 , Brynna Van Wyk  9 , Larissa Yalon  12 , Stuart L Goldstein  13 , Shina Menon  14
Affiliations
Free article

Infant Renal Replacement Therapy Using Carpediem™: A Multicenter Observational Cohort Study from the ICONIIC Learning Network

Cara L Slagle et al. J Pediatr. .
Free article

Abstract

Objective: To evaluate indications and outcomes of Carpediem™ as the first infant-specific continuous renal replacement therapy (CRRT) platform available for clinical use in the US.

Study design: A multicenter, retrospective and prospective observational study was conducted through the "Improving CRRT Outcomes in Neonates and Infants through Interdisciplinary Collaboration (ICONIIC)" Learning Network. Data were collected from the first four US centers utilizing Carpediem™. A treatment course was defined as sequential CRRT procedures separated by ≤72 hours. Infant cohorts were categorized by CRRT indication: end-stage kidney disease (ESKD) (ie, CRRT as a bridge to PD) and non-ESKD (all other indications).

Results: Sixty-seven infants underwent 93 treatment courses using 1,538 filters and 112 vascular access catheters. Primary indication for CRRT was ESKD in 36 (54%) and acute kidney injury in 43%. Median age at first treatment was 18 (IQR: 6, 81) days, and dry weight 2.6 (IQR: 2.4, 3.1) kg for the ESKD cohort and 32 (IQR: 9, 90) days and 3.4 (IQR: 3.2, 4.5])kg for the non-ESKD cohort. Median treatment course duration was 12 (IQR: 3,24) days for ESKD compared with 4 [IQR: 1,13] days for non-ESKD infants. Survival to hospital discharge was 67% in ESKD and 60% in non-ESKD.

Conclusion: In this US cohort study, CRRT survival in infants treated with Carpediem™ exceeds 60%. More than half of the treatment indications were for ESKD as a bridge to dialysis.

Keywords: Carpediem; ICONIIC; acute kidney injury; congenital kidney failure; continuous kidney replacement therapy; end stage kidney disease; fluid overload; infant; neonatal; pediatric.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests ☐ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. ☒ The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Stuart Goldstein reports financial support was provided by Medtronic. Cara Slagle reports a relationship with BIOPORTO DIAGNOSTICS INC that includes: consulting or advisory and travel reimbursement. Cara Slagle reports a relationship with Mozarc Medical Holding LLC that includes: consulting or advisory. Cara Slagle reports a relationship with ExThera Medical that includes: non-financial support. Cara Slagle reports a relationship with Neonatal Kidney Collaboartive that includes: board membership. Katja Gist, Stuart Goldstein, reports a relationship with BIOPORTO DIAGNOSTICS INC that includes: consulting or advisory. Katja Gist, Shina Menon reports a relationship with Gerber Foundation that includes: funding grants. Katja Gist reports a relationship with Fresenius Medical Care AG that includes: speaking and lecture fees. Jennifer Jetton, Katja Gist, Shina Menon reports a relationship with Neonatal Kidney Collaborative that includes: board membership. Shina Menon, Jolyn Morgan, Amanda Snyder reports a relationship with Mozarc Medical Holding LLC that includes: consulting or advisory. Stuart Goldstein reports a relationship with Vantive US Healthcare LLC that includes: consulting or advisory and funding grants. Katie Plomaritas reports a relationship with Vantive US Healthcare LLC that includes: travel reimbursement. Jolyn Morgan, Amanda Snyder reports a relationship with ExThera Medical Corporation that includes: consulting or advisory and non-financial support. Stuart Goldstein reports a relationship with MediBeacon that includes: board membership, consulting or advisory, and equity or stocks. Stuart Goldstein reports a relationship with CalciMedica Inc that includes: consulting or advisory. Stuart Goldstein reports a relationship with Mallinckrodt LLC that includes: consulting or advisory. Stuart Goldstein reports a relationship with Otsuka Pharmaceutical Co Ltd that includes: consulting or advisory. Stuart Goldstein reports a relationship with Seastar Medical that includes: consulting or advisory. Katja Gist reports a relationship with Seastar Medical that includes: consulting or advisory. Stuart Goldstein reports a relationship with Silver Creek Pharmacy Inc that includes: consulting or advisory. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

LinkOut - more resources